7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 
      
    		                                
      operating activities
    		                                
      net income
    		-11,773,000 -7,113,000 -10,659,000 -16,069,000 -7,919,000 -6,029,000 -7,805,000 -6,691,000 -4,591,000 -2,886,000 -6,806,000 -7,848,000 18,539,000 -333,000 -9,100,000 72,000 -2,197,000 -3,756,000 -10,379,000 -14,013,000 -4,539,000 -9,447,000 -4,945,000 -5,429,000 -2,664,000 -2,618,000 -3,020,000 -2,468,000 -1,865,000 -2,692,000 -5,000,000 -4,845,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                                
      goodwill and other intangible asset impairments
    		                                
      depreciation and amortization
    		5,299,000 5,170,000 5,048,000 3,993,000 5,280,000 4,779,000 5,028,000 5,187,000 4,270,000 4,080,000 3,848,000 3,520,000 3,287,000 3,331,000 2,961,000 2,810,000 2,723,000 2,608,000 2,539,000 2,314,000 2,411,000 1,910,000 1,375,000 1,413,000 1,346,000 1,084,000 828,000 715,000 777,000 719,000 681,000 657,000 
      stock-based compensation
    		4,251,000 5,252,000 3,859,000 3,888,000 3,922,000 2,939,000 2,799,000 2,747,000 2,364,000 3,302,000 2,113,000 1,701,000 1,682,000 1,770,000 1,526,000 1,672,000 1,439,000 1,415,000 1,316,000 1,484,000 1,259,000 2,495,000 958,000 707,000 733,000 692,000 471,000 286,000 268,000 454,000 2,177,000 2,397,000 
      loss on early extinguishment of debt
    		   0                             
      accretion of acquisition installment payable
    		7,000 36,000 62,000 62,000 62,000 256,000 281,000 280,000 280,000 431,000 381,000                      
      deferred income taxes
    		-125,000 49,000 196,000 -829,000 -952,000 -510,000 -2,445,000 -264,000 76,000 -401,000 -574,000 -228,000 -4,048,000 -439,000 -317,000 -238,000 -288,000 -290,000 -312,000              
      non-cash other
    		12,000 -239,000 139,000                              
      changes in certain operating assets and liabilities:
    		                                
      accounts receivable - trade
    		3,111,000 -9,884,000 -1,497,000 429,000 -595,000 -5,738,000 1,155,000 3,154,000 -3,914,000 -6,962,000 -2,002,000 1,584,000 1,047,000 -6,616,000 2,000 250,000 1,065,000 -2,434,000 653,000 -62,000 -1,998,000 849,000 760,000 -694,000 373,000 -4,319,000 -1,180,000 276,000 75,000 -2,917,000 -1,235,000 83,000 
      inventories
    		1,006,000 -6,993,000 -1,906,000 957,000 -3,734,000 -3,789,000 -6,631,000 -4,081,000 -10,338,000 -5,881,000 -5,979,000 -2,126,000 -3,907,000 -4,155,000 -6,750,000 -1,806,000 53,000 -789,000 -2,508,000 270,000 -2,741,000 -4,503,000 -5,096,000 -3,276,000 -1,185,000 -3,020,000 -2,286,000 406,000 -1,363,000 -2,522,000 -2,202,000 -1,011,000 
      prepaid expenses and other current assets
    		677,000 18,000 -519,000 573,000 -1,731,000 550,000 -953,000 290,000 -268,000 105,000 -33,000 -1,202,000 139,000 445,000 112,000 -499,000 -244,000 -602,000 708,000 -504,000 -281,000 122,000 -56,000 223,000 -346,000 182,000 -196,000 -211,000 18,000 51,000 -283,000 -216,000 
      accounts payable - trade
    		-5,681,000 -1,487,000 5,207,000 -2,512,000 -5,918,000 -2,412,000 6,562,000 -10,001,000 1,768,000 4,183,000 5,541,000 180,000 -5,687,000 40,000 5,258,000 389,000 -1,147,000 -1,867,000 2,058,000 2,916,000 901,000 -2,485,000 1,739,000 -1,279,000 1,746,000 -439,000 2,373,000 -1,932,000 448,000 -1,742,000 1,702,000 393,000 
      accrued expenses and other liabilities
    		-1,719,000 5,037,000 -2,528,000 229,000 -651,000 6,008,000 -5,049,000 3,564,000 1,963,000 2,896,000 -1,571,000 1,544,000 667,000 1,823,000 -690,000 1,263,000 -1,248,000 634,000 446,000 -516,000 -429,000 1,565,000 -1,694,000 1,935,000 -346,000 1,076,000 -719,000 149,000 -263,000 1,661,000 -600,000 -255,000 
      other
    		191,000 -308,000 -1,558,000 3,366,000 -1,273,000 -2,146,000 368,000 -1,722,000 -1,264,000 -936,000 -709,000 -367,000 1,243,000 -118,000 -222,000 -91,000 -152,000 -203,000 -138,000 -61,000 26,000 -53,000 3,000 -2,000 -138,000 11,000 128,000 -16,000 362,000 -459,000 82,000 -58,000 
      net cash from operating activities
    		-581,000 -10,462,000 -4,156,000 -3,987,000 -10,279,000 -6,092,000 -6,690,000 -7,543,000 -8,669,000 -4,373,000 -6,461,000 -3,341,000 -6,058,000 -8,170,000 -4,197,000 -1,235,000 -937,000 -8,976,000 -1,915,000 -157,000 -3,666,000 -7,751,000 -6,956,000 -6,926,000 -429,000 -6,943,000 -3,471,000 -2,728,000 -1,182,000 -6,640,000 -5,033,000 -3,323,000 
      capex
    		-2,839,000 -3,445,000 -4,227,000 262,000 -1,381,000 -6,684,000 -6,460,000 -3,836,000 -2,479,000 -5,623,000 -4,940,000 523,000 -1,089,000 -5,268,000 -4,197,000 -1,635,000 -1,994,000 -1,725,000 -2,749,000 -4,056,000 -1,288,000 -1,207,000 -3,953,000 -1,280,000 -2,022,000 -3,551,000 -4,963,000 58,000 -1,144,000 -1,396,000 -2,771,000 -1,258,000 
      free cash flows
    		-3,420,000 -13,907,000 -8,383,000 -3,725,000 -11,660,000 -12,776,000 -13,150,000 -11,379,000 -11,148,000 -9,996,000 -11,401,000 -2,818,000 -7,147,000 -13,438,000 -8,394,000 -2,870,000 -2,931,000 -10,701,000 -4,664,000 -4,213,000 -4,954,000 -8,958,000 -10,909,000 -8,206,000 -2,451,000 -10,494,000 -8,434,000 -2,670,000 -2,326,000 -8,036,000 -7,804,000 -4,581,000 
      investing activities
    		                                
      acquisition of boston o&p, net of cash acquired
    		   0 468,000 0 -20,693,000                          
      acquisitions, net of cash acquired
    		                                
      sale of short-term marketable securities
    		   0 0 26,381,000 23,474,000 23,864,000 16,693,000 35,097,000 37,250,000 1,343,000 13,929,000 13,100,000 18,500,000                  
      investment in private companies
    		-467,000 0 -1,540,000                              
      purchase of short-term marketable securities
    		   0    0 -4,000,000   -25,093,000                     
      purchases of property and equipment
    		-2,839,000 -3,445,000 -4,227,000 262,000 -1,381,000 -6,684,000 -6,460,000 -3,836,000 -2,479,000 -5,623,000 -4,940,000 523,000 -1,089,000 -5,268,000 -4,197,000 -1,635,000 -1,994,000 -1,725,000 -2,749,000 -4,056,000 -1,288,000 -1,207,000 -3,953,000 -1,280,000 -2,022,000 -3,551,000 -4,963,000 58,000 -1,144,000 -1,396,000 -2,771,000 -1,258,000 
      net cash from investing activities
    		-26,838,000 -3,545,000 -5,987,000 -2,412,000 -26,768,000 19,697,000 -3,679,000 17,922,000 9,668,000 -18,223,000 32,310,000 -23,227,000 -103,919,000 -528,000 14,303,000 2,965,000 -3,044,000 -1,725,000 -5,607,000 -59,056,000 -1,288,000 -3,726,000 -5,623,000 -1,529,000 -1,736,000 -53,675,000 -4,982,000 -459,000 -1,159,000 -1,417,000 -2,930,000 -1,258,000 
      financing activities
    		                                
      proceeds from issuance of debt
    		0   0                             
      payments on mortgage notes
    		-41,000 -39,000 -39,000 -39,000 -42,000 -36,000 -35,000 -37,000 -36,000 -35,000 -36,000 -35,000 -35,000 -34,000 -33,000 -34,000 -33,000 -32,000 -32,000 -37,000 -27,000 -30,000 -31,000 -30,000 -29,000 -30,000 -29,000 -29,000 -28,000 -28,000 -28,000 2,000 
      payment of debt issuance costs
    		   -322,000 -2,742,000                            
      payment on debt
    		   0                             
      installment payment for apifix
    		   0 0   0 0   0 0                    
      installment payment for medtech
    		   0 0                            
      payments on clinic acquisition notes
    		-241,000 -161,000 -87,000                              
      net cash from financing activities
    		-282,000 24,800,000 -126,000 -541,000 58,518,000 -4,269,000 -573,000 9,387,000 -15,000 -2,035,000 -36,000 -35,000 108,268,000 27,774,000 -33,000 -34,000 42,000 -32,000 30,000 -16,000 -19,679,000 70,957,000 -4,530,000 59,966,000 455,000 30,062,000 536,000 39,415,000 298,000 -28,000 -28,000 44,925,000 
      effect of exchange rate changes on cash, cash equivalents and restricted cash
    		-20,000 383,000 -79,000  684,000 -2,010,000 1,479,000  -61,000 -197,000 -138,000                      
      net increase in cash, cash equivalents and restricted cash
    		-27,721,000    22,155,000 7,326,000 -9,463,000  923,000 -24,828,000 25,675,000                      
      cash, cash equivalents and restricted cash, beginning of year
    		0 0 45,777,000  0 0 33,027,000  0 0 10,462,000                      
      cash, cash equivalents and restricted cash, end of period
    		-27,721,000 11,176,000 35,429,000  22,155,000 7,326,000 23,564,000  923,000 -24,828,000 36,137,000                      
      clinic acquisition, net of cash acquired
    		 -100,000 -220,000                              
      net decrease in cash, cash equivalents and restricted cash
    		  -10,348,000                              
      supplemental disclosures
    		                                
      cash paid for interest
    		  1,269,000   537,000 223,000   0 11,000 188,000 452,000 47,000 13,000 13,000 14,000 14,000 15,000 15,000 705,000 134,000 379,000 1,997,000 1,297,000 632,000 303,000 533,000 608,000 562,000 552,000 634,000 
      transfer of instruments between property and equipment and inventory
    		  -461,000   164,000 117,000                          
      right-of-use assets obtained in exchange for lease liabilities
    		  1,682,000                              
      issuance of common shares in connection with boston o&p acquisition
    		  233,000                              
      impairment
    		                                
      fair value adjustment of contingent consideration
    		       -6,000 0 -2,304,000 -670,000 -480,000 -23,010,000 -5,010,000 2,570,000 -5,510,000 -1,430,000 990,000 4,150,000 1,701,000 909,000            
      clinic acquisitions, net of cash acquired
    		                                
      acquisition of medtech, net of cash acquired
    		                                
      acquisition of rhino assets
    		                                
      acquisition of mdo, net of cash acquired
    		                                
      acquisition of pega, net of cash acquired
    		           0                     
      investment in private companies and purchases of licenses
    		                                
      payments on debt with affiliate
    		           0                     
      proceeds from issuance of debt with affiliate
    		           0 0           0 0       -2,147,000 
      proceeds from issuance of common stock, net of issuance costs
    		           0        0 0            
      proceeds from exercise of stock options
    		       0    0 21,000   0 75,000 0 62,000 21,000 348,000 593,000 688,000 0 484,000 92,000 565,000 84,000     
      effect of exchange rate changes on cash
    		           193,000 26,000 159,000 241,000 -392,000 -295,000 -126,000 155,000 -380,000 -41,000 -6,000 23,000          
      net increase in cash and restricted cash
    		           -26,410,000                     
      cash and restricted cash, beginning of period
    		                                
      cash and restricted cash, end of period
    		           -26,410,000 -1,683,000 19,235,000 19,320,000 1,304,000 -4,234,000 -10,859,000 22,795,000 -59,609,000 -24,674,000 59,474,000 54,941,000          
      issuance of common shares for apifix installment
    		                                
      issuance of common shares to acquire medtech
    		                                
      issuance of common shares for medtech installment
    		                                
      issuance of common shares to acquire rhino assets
    		                                
      issuance of common shares to acquire mdo
    		                                
      debt issuance costs not yet paid
    		                                
      tradename impairment
    		                                
      payments on acquisition note
    		    0 -390,000 -538,000                          
      acquisition of medtech
    		        0                        
      trademark impairment
    		       0    0                     
      changes in certain current assets and liabilities:
    		                                
      accrued legal settlements
    		               0 0 -5,250,000 -1,092,000              
      acquisition of devise ortho assets
    		                                
      purchases of licenses
    		               0 -5,050,000 0 -2,858,000     -100,000 0 -151,000 -19,000 -15,000 -15,000 -21,000 -159,000 0 
      issuance of common shares for apifix acquisition installment
    		           0                     
      issuance of common shares to purchase devise ortho assets
    		                                
      acquisition of md ortho, net of cash acquired
    		            0                    
      acquisition of pega medical, net of cash acquired
    		                                
      acquisition of rhino
    		                                
      issuance of common shares to acquire md ortho
    		            0                    
      transfer of instruments from property and equipment to inventory
    		          332,000 -41,000 -63,000 -76,000 -54,000 373,000 -250,000 273,000 57,000 -230,000 416,000 47,000 182,000 444,000 326,000 50,000 217,000 -699,000 467,000 290,000 304,000 53,000 
      acquisition installment payable
    		           381,000 381,000 1,092,000 453,000 453,000 489,000 568,000 644,000 695,000 816,000            
      acquisition of telos, net of cash acquired
    		                   0 0 0 -1,670,000          
      acquisition of apifix, net of cash acquired
    		                   0 0            
      acquisition of band-lok intangible assets
    		                   0 0            
      issuance of common shares to acquire telos
    		                   0 0 -182,000 1,750,000          
      issuance of common shares to acquire apifix
    		                   0 0            
      issuance of common shares to purchase band-lok intellectual property
    		                                
      cash and restricted cash, beginning of year
    		            0 0 9,006,000  0 0 30,132,000  0 0 72,027,000          
      net increase in cash
    		             19,235,000 10,314,000  -4,234,000    -24,674,000       36,228,000 -2,043,000 -8,085,000 -7,991,000 40,344,000 
      building and building improvements
    		             0 25,000    25,000    25,000 0 0 0 25,000 0 0 0 25,000 0 
      furniture and fixtures
    		             0 5,000    5,000    5,000 0 0 0 5,000 0 0 0 5,000 0 
      computer equipment
    		             0 3,000    3,000    3,000 0 0 0 3,000 0 0 0 3,000 0 
      business software
    		             0 3,000    3,000    3,000 0 0 0 3,000 0 0 0 3,000 0 
      office and other equipment
    		             0 5,000    5,000    5,000 0 0 0 5,000 0 0 0 5,000 0 
      instruments
    		             0 5,000    5,000    5,000 0 0 0 5,000 0 0 0 5,000 0 
      sample inventory
    		             0 2,000    2,000    2,000 0 0 0 2,000 0 0 0 2,000 0 
      loss on sale of discontinued operations
    		                                
      net cash from operating activities - continuing operations
    		                   -157,000 -3,666,000   -6,192,000 -648,000        
      net cash used by operating activities - discontinued operations
    		                                
      acquisition of vilex and orthex, net of cash acquired
    		                        239,000        
      sale of short term investments
    		                                
      purchase of short term investments
    		                                
      payments on note with affiliate
    		                     0 -5,000,000          
      issuance of common shares to acquire vilex and orthex
    		                                
      divestiture consideration allocated to assets held for sale
    		                                
      payment of term note b with revolving credit facility
    		                                
      issuance of common shares to acquire band-lok intellectual property
    		                                
      repurchases of common shares
    		                      -187,000          
      net decrease in cash
    		                  -7,337,000    -17,086,000  -1,710,000 -30,556,000 -7,917,000      
      purchase of notes receivable
    		                                
      payment of revolving credit facility with affiliate
    		                                
      issuance of common share sto acquire vilex and orthex
    		                                
      net cash from operating activities - discontinued operations
    		                        219,000        
      less cash of discontinued operations, end of period
    		                        479,000        
      cash of continuing operations, end of period
    		                    -24,674,000    -2,189,000        
      net cash from investing activities - continuing operations
    		                                
      net cash from investing activities - discontinued operations
    		                                
      issuance of common shares to acquire band-lok
    		                                
      acquisition of vilex, net of cash acquired
    		                                
      payment of preferred stock dividends
    		                                
      shares surrendered by employees to pay taxes on restricted shares
    		                                
      cash, beginning of year
    		                       0 0 0 60,691,000 0 0 0 42,582,000 0 
      accretion of redeemable convertible preferred stock
    		                               199,000 
      acquisition consideration of common shares
    		                       0 0        
      intellectual property license
    		                                
      cash, end of period
    		                        -1,710,000 -30,556,000 52,774,000 36,228,000 -2,043,000 -8,085,000 34,591,000 40,344,000 
      inventories held by international distributors
    		                         37,000 130,000 67,000 361,000 807,000 -355,000 -468,000 
      research and development fee obligation
    		                                
      payments of deferred offering costs
    		                                
      loss on sale of assets held for sale
    		                                
      proceeds from assets held for sale
    		                                
      research and development fee obligation termination
    		                                
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.